Edward Agyare to Carcinoma, Pancreatic Ductal
This is a "connection" page, showing publications Edward Agyare has written about Carcinoma, Pancreatic Ductal.
Connection Strength
0.625
-
Akin-Olugbemi O, Lucas D, Okoro J, Frimpong E, Bulusu R, Stone R, Flores-Rozas H, Agyare E, Jackson T, Ablordeppey S, Mohammed S, Vintilla B, Herremans K, Underwood PW, Delitto D, Thompson G, Riner AN, Trevino J, Hughes SJ, Han S, Yoon SL, Gobin C, Salhia B, Okunieff P, Fredenburg KM, Allen JM, Machona B, Reams RR, Wilkie DJ. Building Equitable Cancer Research Infrastructure: Successful Transfer of Patient-Derived Xenograft Technology to a Historically Black University. Cancer Control. 2025 Jan-Dec; 32:10732748251401261.
Score: 0.222
-
Barajas J, Yang Z, Agyare E, Zhu X, Yoon SJ, Han B. Matrix stiffness influences drug resistance to gemcitabine analog and AZD 1775 combination in PDAC organoids. PLoS One. 2025; 20(12):e0326550.
Score: 0.221
-
Telisnor G, DeRemer DL, Frimpong E, Agyare E, Allen J, Ricks-Santi L, Han B, George T, Rogers SC. Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans. J Natl Med Assoc. 2023 Apr; 115(2):164-174.
Score: 0.182